IMV Inc

NASDAQ:IMV  
2.68
+0.07 (+2.68%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)181.46M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.03 Million
Adjusted EPS-$0.12
See more estimates
10-Day MA$2.73
50-Day MA$3.06
200-Day MA$3.71
See more pivots

IMV Inc Stock, NASDAQ:IMV

130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia B3B 2C4
Canada
Phone: +1.902.492.1819
Number of Employees:

Description

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.